3月4日 - ** 药物开发商Amylyx Pharmaceuticals的AMLX.O股价下跌3.5%，至2.89美元
** (link) 公司第四季度净亏损 3750 万美元，而去年同期净收入为 470 万美元。
** AMLX 完成了 1,970 万股的包销公开发售，净收益约为 6,550 万美元。
** 此次发行将公司的现金流延长至2026年底
** 在过去 12 个月中，AMLX 下跌了 84
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.